Top Emerging Trends Of Hospital Acquired Infections (HAI) Diagnostics Market Progress Forecast 2022 |Grand View Research, Inc.
Global hospital acquired infections diagnostics
market is expected to reach USD
11.6 billion by 2022, according to a new report by Grand View Research, Inc.
A surge in hospital traffic due to admissions for Covid-19 cases has increased the burden of hospital-acquired
infections. The overpopulation of major healthcare infrastructure due to the Covid-19 pandemic is a key aspect taken
into account while updating the market model for this report.
Some major
players actively involved in the industry are bioMérieux, Abbott Laboratories,
Roche AG, and Siemens Healthcare among others. In an attempt
to ensure sustainability and register growth, the companies adopted several
strategies such as partnerships, joint ventures, new product developments,
collaborations, and acquisitions.
The global hospital acquired
infections diagnostics market is projected to grow at a healthy CAGR during the
period of 2015 to 2022. Factors attributing to the growth of the market are
increase in the number of drug-resistant pathogens such as MRSA and C.
difficile, advancing age of geriatric population, and development of
technologically advanced products that offer accurate and reliable results with
low turnaround time.
Another factor contributing to
industry growth is the increasing demand of HAI diagnostics from middle and low
income countries, further driving demand for HAI diagnostic market. Increasing
awareness among healthcare workers and proposed government initiatives are
further supporting industry growth. However, decline in the prevalence rate of
nosocomial infections in the developed countries is likely to hinder industry
growth.
To Request Sample Copy of this report, click the link:
The HAI diagnostics market is
categorized on the basis of infection type and test type. On the basis of
infection type, the market is segmented into Urinary Tract Infection (UTI),
Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and
others. As of 2015, the urinary tract infection segment was estimated to
account for the largest share, whereas the pneumonia HAI diagnostics is
projected to grow at the highest CAGR during the period of 2015 to 2022.The HAI
diagnostics industry is further segmented into molecular tests and other
in-vitro tests. Though the molecular diagnostics segment is estimated to
constitute a low share, it is anticipated to witness a lucrative growth in the
next few years.
Further key findings from the study
suggest:
·
In the year 2015, North America
held the largest share in the industry in terms of value. The rising awareness
of HAI, application of technologically advanced products, and significant
measures taken by the government to counter HAIs are some of the major factors
contributing to industry growth.
·
The AsiaPacific is projected to
witnessthe highest growth in the coming years, as incidence of HAIs is on rise
in the region. This market is projected to grow rapidly at the highest CAGR of
around 20% during the period 2015 to 2022.
·
As of 2015, the diagnostic
market for UTI acquired in hospitals led the industry at a global level. On the
other hand, the pneumonia segment is expected to witness the highest growth
over the forecast period.
·
The industry constitutes of
numerous local and global players. Some key players of this market include
bioMérieux, Abbott Laboratories, Roche AG, and Siemens Healthcare among
others.
The
global Hospital Acquired Infection (HAI) diagnostic market size was estimated
to be USD 3.6 billion in 2015. HAIs have been of increasing concern in
healthcare facilities across the globe. According to the WHO, among hundred
patients in hospitals, ten patients are estimated to suffer from HAIs in
developing countries, and seven in developed countries.
In
developed countries, after cancer and cardiovascular diseases, HAI is
considered to be the third leading reason for mortality. In the U.S. and
European regions, six million patients are affected every year, resulting in
around150,000 deaths.
The
industry is anticipated to witness a significant growth in the next few years.
One of the key factors driving industry growth is the rising geriatric
population base. Advancing age of the geriatric population makes them more
vulnerable and prone to diseases, thus increasing the demand for diagnosis.
Other aspects supporting industry growth are growing demand of
HAI diagnostics from middle and low-income countries such as India and Brazil,
development of technologically advanced diagnostic products, rising awareness
among healthcare workers, and initiatives taken by governments to counter the
prevalence of HAIs.
However, decreasing prevalence of nosocomial infections in the developed countries owing to improved healthcare infrastructure and rising awareness are expected to restrict industry growth.
The HAI diagnostic market is
broadly classified into Blood Stream Infections (BSI), Urinary Tract Infections
(UTI), Surgical Site Infections (SSI), pneumonia/lower respiratory infections,
and others such as cardiovascular and gastro intestinal infections. The UTI
diagnostics market is expected to lead the market with the largest share in the
year 2015, whereas the industry for diagnosis of pneumonia as a nosocomial
infection is anticipated to witness the highest growth in the industry during
the forecast period.
Browse Press
Release of this report:
Grand View Research has segmented the
global hospital acquired infections diagnostic market on the basis of infection
type, test type:
Hospital Acquired Infections Diagnostic Infection Type
Outlook (Revenue, USD Million, 2012 - 2022)
·
Bloodstream Infections (BSI)
·
Urinary Tract Infections (UTI)
·
Surgical Site Infections (SSI)
·
Pneumonia
·
Others
Hospital Acquired Infections Diagnostic Test Type Outlook
(Revenue, USD Million, 2012 - 2022)
·
Molecular Diagnostics Tests
·
Other In-vitro Diagnostic Tests
On the basis of types of tests, the
industry is segmented into molecular diagnostics and other IVD tests including
urinalysis and blood tests. The molecular diagnostics segment is projected to
grow at the highest CAGR during the period of 2015 to 2022. Rapid results with
less turnaround time, high sensitivity, and accuracy are some of the factors
attributing to industry growth in the near future.
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment